Abstract
Introduction
Human induced pluripotent stem cells (hiPSCs) offer a unique opportunity for disease modeling. However, it is not invariably successful to recapitulate the disease phenotype because of the immaturity of hiPSC-derived cardiomyocytes (hiPSC-CMs). The purpose of this study was to establish and analyze iPSC-based model of catecholaminergic polymorphic ventricular tachycardia (CPVT), which is characterized by adrenergically mediated lethal arrhythmias, more precisely using electrical pacing that could promote the development of new pharmacotherapies.
Method and Results
We generated hiPSCs from a 37-year-old CPVT patient and differentiated them into cardiomyocytes. Under spontaneous beating conditions, no significant difference was found in the timing irregularity of spontaneous Ca 2+ transients between control-and CPVT-hiPSCCMs. Using Ca 2+ imaging at 1 Hz electrical field stimulation, isoproterenol induced an abnormal diastolic Ca 2+ increase more frequently in CPVT-than in control-hiPSC-CMs (control 12% vs. CPVT 43%, p<0.05). Action potential recordings of spontaneous beating hiPSC-CMs revealed no significant difference in the frequency of delayed afterdepolarizations (DADs) between control and CPVT cells. After isoproterenol application with pacing at
Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a hereditary arrhythmic disorder characterized by bidirectional ventricular tachycardia (VT) that is triggered by emotional stress or physical exercise and leads to syncope or sudden cardiac death without structural heart disease. CPVT is caused by autosomal dominant mutations in the cardiac ryanodine receptor gene (RyR2) [1] , the calmodulin gene (CALM1, CALM2) [2, 3] and the inward rectifying potassium channel gene (KCNJ2) [4] and autosomal recessive mutations in the cardiac calsequestrin gene (CASQ2) [5] and the triadin gene (TRDN) [6] . Approximately 50-55% of CPVT cases are associated with RyR2 mutations [7] and 1-2% are due to CASQ2 mutations [8] . Beta-blockers are the first-line therapy for CPVT, but they often fail to prevent fatal arrhythmias [9] . Recently, flecainide, a class Ic Na + channel blocker, has been reported to be effective for treating CPVT patients [10] . The advent of human induced pluripotent stem cell (hiPSC) technology has enabled us to use human cardiomyocytes that have the same genetic background as the patients. There have been several reports of CPVT iPSC-based model [11] [12] [13] [14] [15] , however, it is becoming clearer that hiPSC-derived cardiomyocytes (hiPSC-CMs) have immature electrophysiological and structural properties compared to adult human cardiomyocytes [16, 17] , which hamper us to analyze their phenotype precisely. In the present study, we demonstrated that hiPSC-CMs beat in an irregular disorganized pattern even in those of control, and suggested the usefulness of electrical pacing during Ca 2+ transient and action potential (AP) recordings in hiPSC-CMs. In addition, we investigated the efficacy of S107, a 1,4-benzothiazepine derivative that is a promising candidate drug for treating CPVT. S107 was discovered by Marks et al and reported to correct leaky RyR1, 2 by stabilizing interactions between RyR 1, 2 and calstabin 1, 2 [18] . The potency of S107 for preventing the development of DADs in CPVT-hiPSC-CMs indicates that our model could be useful for investigating new pharmacotherapies.
Materials and Methods

hiPSC generation and cardiomyocyte differentiation
Human dermal fibroblasts were obtained from a patient after written informed consent was obtained. The fibroblasts were retrovirally transduced with a combination of 4 transcription factors (Oct3/4, Sox2, Klf-4, c-Myc) to generate hiPSCs. This study was approved by Kyoto University ethics review board (G259) and conformed to the Declaration of Helsinki. All patients provided written informed consent. The control hiPSC line, 201B7, was generated
Genomic sequencing and karyotyping
Genomic DNA was isolated from control and CPVT-hiPSC lines by GenElute Mammalian Genomic DNA Miniprep kit (Sigma-Aldrich, St Louis, MO, USA). Purified DNA was amplified with specific primers and analyzed by 3100 Genetic Analyzer and Big Dye Terminator v1.1 (Applied Biosystems, Foster City, CA, USA). Chromosomal G-banding analysis was performed using a standard procedure (Nihon Gene Research Laboratories, Sendai, Japan). Primers are detailed in S1 Table. Immunocytochemistry
The hiPSC colonies were fixed in 4% paraformaldehyde (PFA) for 20 min. The cells were permeabilized in 0.2% Triton X-100 (Nacalai Tesque). 18 primer with Transcriptor First Strand cDNA Synthesis Kit (Roche). TaqMan real-time PCR assay was performed using FastStart Universal Probe Master (Rox) and an appropriate probe from Universal ProbeLibrary Set (Roche). The expression of genes of interest was normalized to that of GAPDH. Relative quantification was calculated according to the ΔΔC T method. The changes in gene expression levels were compared with those of adult human heart. The fold change is expressed as mean ± SEM. A list of the primers used in these experiments is provided in S1 Table. Ca 2+ imaging
The hiPSC-CMs were dispersed with collagenase B and Trypsin EDTA and plated onto glass coverslips coated with fibronectin (BD Biosciences, San Jose, CA, USA). After 5-7 days, dissociated hiPSC-CMs on a coverslip were loaded with 2 μmol/L Fluo-8 (AAT Bioquest, Sunnyvale, CA, USA) in the culture medium described above. After incubation for 30 min at 37°C in 5% CO 2 
Electrophysiological recordings
The hiPSC-CMs were enzymatically dissociated with collagenase B and Trypsin EDTA and plated onto glass coverslips coated with fibronectin (BD Biosciences). APs were recorded at 36.0 ± 1.0°C in a current clamp mode using a perforated patch-clamp technique. The pipette solution contained 300 μg/ml amphotericin B (Sigma-Aldrich, St Louis, MO, USA) and the following (in mM): 150 KCl, 5 EGTA, 5 MgATP, 10 HEPES, 5 NaCl, 2 CaCl 2 , pH was adjusted to 7.2 by KOH. The experiments were performed under continuous perfusion of the extracellular solution containing (in mM): 150 NaCl, 5.4 KCl, 1.8 CaCl 2 , 1 MgCl 2 , 15 glucose, 15 HEPES, 1 Na-pyruvate (pH adjusted to 7.40 with NaOH) [22] . Patch-clamp pipettes, formed from borosilicate glass with PP-830 (Narishige, Tokyo, Japan) and had a resistance of 4-7 MΩ. APs were recorded from spontaneously contracting and quiescent hiPSC-CMs. All signals were acquired at 10 kHz, digitized with a Digidata 1332A (Axon instruments, CA, USA) and analyzed with a pCLAMP 10.4 software (Axon instruments). Current clamp recordings were performed using a MultiClamp 700B amplifier. Solutions containing 100 nM isoproterenol were applied using a gravitational flow system 5-10 min prior to data collection. We added 1 and 10 μM freshly prepared S107 (Cayman Chemical, Ann Arbor, MI, USA) to the culture medium 2-3 hours prior to the experiments.
Statistical analysis
Continuous variables are presented as the mean ± SEM. Categorical variables are expressed as frequencies. Differences in the means between two groups were compared using Student's ttests. Categorical differences between two groups were evaluated using chi-squared tests. A value of p < 0.05 was considered statistically significant.
Results
Generation of patient-specific CPVT-hiPSCs
We generated hiPSCs from a 37-year-old female patient with CPVT, whose clinical features were previously reported [23] . She first experienced syncope during running or swimming at 15 years of age. Her next episodes of syncope were while riding a bicycle and when under emotional stress caused by a traffic accident at 30 years of age. She then remained free of syncope until the age of 36 years when she experienced an episode upon awakening from a nightmare, at which time she was admitted to the hospital. Polymorphic VT was recorded during an exercise test and an epinephrine provocation test. She was diagnosed with CPVT and began taking carvedilol. However, she had an episode of syncope and polymorphic VT was recorded again during an exercise test despite having received an oral beta-blocker. Subsequently, she underwent implantation of an implantable cardioverter-defibrillator (ICD). At the age of 37, an appropriate ICD discharge occurred and she began taking flecainide, which was effective in preventing polymorphic VT. Genetic analyses identified a missense mutation, c.13759 A>G, p. I4587V, in the RyR2 gene. Her son also had a history of syncope and was a carrier of an identical mutation. Dermal fibroblasts were obtained from the proband and retrovirally transduced with 4 genes (Oct3/4, Sox2, Klf-4, and c-Myc). As a control, we used an hiPSC line, 201B7, which was similarly generated from a healthy individual [19] . The CPVT-hiPSCs exhibited characteristic human embryonic stem cell morphology and stained positively for pluripotency markers (OCT3/4, SSEA4, TRA1-60) (Fig 1A) . The CPVT-hiPSC lines displayed a normal karyotype (Fig 1B) . We confirmed the RyR2-I4587V mutation in the CPVT-hiPSCs, but not in the control-hiPSCs (Fig 1C) . In order to confirm the pluripotency of generated hiPSCs, we injected hiPSCs into severe combined immunodeficiency (SCID) mice, which led to the formation of teratomas, containing tissue derivatives of three germ layers: pigmented epithelium (ectoderm), gut-like structures (endoderm), and cartilage tissue (mesoderm) (Fig 1D) .
Gene expression of hiPSC-CMs
We differentiated control-and CPVT-hiPSCs into spontaneously contracting cardiomyocytes using an EB differentiation system. Spontaneously beating EBs started to appear at day 7 of differentiation. EBs were plated on fibronectin-coated dishes at day 21 and maintained in the culture medium described above for an additional 2 months. We conducted quantitative real-time PCR in control-and CPVT-hiPSC-CMs at days 30 and 90, and the expression levels of the genes involved in Ca 2+ handling are shown in Fig 2. Consistent with previously reported transcriptional profile data on human iPSC/ESC-derived cardiomyocytes [24] , CASQ2 expression levels were extremely low compared to those of adult human cardiomyocytes. However, RyR2 and SERCA2 were already expressed at 1 month similar to adult human myocytes in the control-and CPVT-hiPSC-CMs. Innositol-1,4,5-trisphosphate receptor 2 (IP3R2) and calreticulin were highly expressed in the control-and CPVT-hiPSC-CMs compared to adult human cardiomyocyts (Fig 2) . In this study, there was no significant difference in Ca 2+ handling gene expression between control-and CPVT-hiPSC-CMs.
CPVT-hiPSC-CMs presented diastolic Ca 2+ waves with adrenergic stimulation upon Ca 2+ imaging
We performed Ca 2+ imaging of spontaneously contracting control-and CPVT-hiPSC-CMs. A considerable number of both control-and CPVT-hiPSC-CMs showed irregular beating rhythms at baseline and after isoproterenol administration (Fig 3A) . To evaluate the irregularity parameter, we calculated the cycle length variability index, also known as the coefficient of variation, defined as the cycle length standard deviation divided by the mean of the cycle length. The cycle length variability indices were higher in hiPSC-CMs compared to those in isolated rabbit nodal cells [25] , but there was no significant difference between control and CPVT cells (Fig 3B) . In spontaneous beating hiPSC-CMs, we found no significant difference in the frequency of diastolic Ca 2+ waves (increased intracellular Ca 2+ concentration during the diastolic phase) between control and CPVT cells (Fig 3C) . Therefore, to minimize the effect of beating intervals, we used electrical field stimulation when recording Ca 2+ transients to assess the arrhythmic phenotype in hiPSC-CMs (Fig 4A) . At baseline, CPVT-hiPSC-CMs showed diastolic Ca 2+ waves significantly more frequently than control-hiPSC-CMs at 0.5 Hz pacing (CPVT: 33%, control: 4%; p < 0.05; Fig 4B) . After administration of 100 nM isoproterenol, significantly more frequent diastolic Ca 2+ waves were recorded in CPVT-hiPSC-CMs than control-hiPSC-CMs (CPVT: 58%, control: 20% at 0.5 Hz; p < 0.05; CPVT: 43%, control: 12% at 1 Hz; p < 0.05; Fig 4B) . We treated the CPVT-hiPSC-CMs with ryanodine, a strong ligand of the ryanodine receptor (Fig 5A) . With 10 μM ryanodine, the percentage of CPVT-hiPSC-CMs that presented diastolic Ca 2+ waves after isoproterenol administration significantly decreased to 9% at 0.5 Hz and 7% at 1 Hz pacing (Fig 5B) . 
β-adrenergic stimulation-induced DADs in CPVT-hiPSC-CMs
The percentage of CPVT-hiPSC-CMs that developed DADs during AP recordings did not differ from that of control-hiPSC-CMs under the spontaneously beating condition at baseline and after isoproterenol administration (Fig 6A and 6B) . Under regular electrical stimulation, AP Fig 6C and 6D) . However, administration of isoproterenol at 100 nM produced significantly more frequent DADs in CPVT-hiPSC-CMs than control-hiPSC-CMs (CPVT: 86%, control: 30% at 1 Hz; p < 0.05; CPVT: 69%, control: 29% at 1.5 Hz; p < 0.05; Fig 6D) . We 
S107 exerted an antiarrhythmic effect on CPVT-hiPSC-CMs
We treated CPVT-hiPSC-CMs with the 1,4-benzothiazepine derivative S107. Pre-incubation with S107 for 2-3 hours suppressed the frequency of DADs in CPVT-hiPSC-CMs in a concentration-dependent manner (Fig 7A) . Incubation with 1 μM S107 significantly decreased the percentage of CPVT-hiPSC-CMs presenting DADs to 33% at 1 Hz pacing after isoproterenol administration. Incubation with 10 μM S107 further decreased the percentage of CPVThiPSC-CMs with DADs compared to those lacking S107 (25% at 1 Hz; p < 0.05, 10% at 1.5 Hz; p < 0.05; Fig 7B) . 
Discussion
Since the recognition of RyR2 as a gene responsible for CPVT [1] , functional analyses have suggested that DADs following Ca 2+ leakage from the sarcoplasmic reticulum (SR) are associated with ventricular arrhythmia in CPVT; however, the mechanisms underlying SR Ca 2+ leak have not been elucidated. Even now, some patients with CPVT experience syncope or sudden cardiac death. Although we must develop novel therapeutic approaches, it is uncertain whether the results of drug testing in mouse models are replicated in humans. Patient-specific hiPSCbased models of CPVT offer new opportunities for studying drug effects and pathogenetic mechanisms in human cardiomyocytes, however, it is not invariably successful to recapitulate the phenotypes due to the electrophysiological immaturity of hiPSC-CMs. In this study, we precisely evaluated the electrophysiological properties using electrical pacing, and confirmed abnormal diastolic Ca 2+ waves during Ca 2+ imaging and DADs during AP recordings in CPVT-hiPSC-CMs, which are two major phenotypes shown in CPVT knock-in mouse models [26, 27] . In addition, S107 prevented the development of DADs in CPVT-hiPSC-CMs. the maturation of the hESC-CMs [28] . For the first time, we showed that IP3R2 was highly expressed in hiPSC-CMs compared to adult human cardiomyocytes. IP3-dependent Ca 2+ signaling has been shown to play an important role during the process of cardiac development. Calreticulin is also an important Ca 2+ buffer and a regulator of Ca 2+ homeostasis during fetal life. High expression levels of IP3R2 and calreticulin, together with extremely low expression levels of CASQ2, indicate immature Ca 2+ handling properties in hiPSC-CMs.
The hiPSC-CMs have irregular beating rhythms resulting from immature electrophysiological properties, which hamper the precise electrophysiological analyses. The cycle length variability indices of spontaneously beating control-and CPVT-hiPSC-CMs were remarkably higher compared to those of rabbit pacemaker cells [25] , indicating highly irregular contraction of hiPSC-CMs. Under spontaneously beating conditions, there were no significant differences in the frequency of diastolic Ca 2+ waves or DADs between control-and CPVT-hiPSC-CMs. Ca 2+ transients, ion currents (I ca(L) , I to , I NaK and I NaL ), and intracellular ion concentrations (Na + and K + ) in myocytes were reported to vary depending on pacing frequency using in-silico analyses [29, 30] . Therefore, we used electrical stimulation to perform the experiments at equal beating rates and successfully demonstrated significantly more frequent diastolic Ca 2+ waves
and DADs in CPVT-hiPSC-CMs compared to control cells. Kujala et al reported the presence of early afterdepolarizations in CPVT-hiPSC-CMs [14] ; however, in our experiments, we did ) of CPVT-hiPSC-CMs that showed DADs after isoproterenol administration with and without S107 pre-incubation. S107 suppressed DADs in a concentration-dependent manner. *p < 0.05 versus the absence of S107. -permeable channel and consists of the N-terminal, central, and C-terminal domains [31] . The C-terminal domain is composed of the Idomain and the transmembrane domain which forms the channel pore. K201 (JTV519), a 1,4-benzothiazepine derivative, was formerly a promising candidate drug for CPVT and was thought to stabilize RyR2 by correcting defective domain-domain interactions in the N-terminal and central domains. K201 prevented the SR Ca 2+ leak in failing cardiomyocytes by improving the defective inter-domain interaction between the N-terminal and central domains [32] . However, it failed to present cardioprotective effects on catecholamine-induced DADs and arrhythmia generation in the R4496C +/-mouse model of CPVT with a mutation in the RyR2 transmembrane domain [26] . In addition, K201 was reported to be a multichannel blocker that suppressed I Ca(L) and I NCX (33 ± 5% reduction in the peak I ca(L) with 0.3 μM K201, the concentration generally used in in vitro assays) [33] . In this context, another 1,4-benzothiazepine derivative, S107, was developed. S107 is one of the Rycals1, small molecules that prevent Ca 2+ leakage from the SR by promoting the binding of calstabin or calstabin2 (a channel stabilizing protein) to ryanodine receptor isoform 1 or RyR2. S107 has high specificity for RyR2 and no off-target activity up to 10 μM [18] . In mouse model studies, S107 was effective for preventing ventricular arrhythmias, seizures and atrial fibrillation in CPVT [18] . In the present study, we first confirmed the efficacy of S107 in CPVT-hiPSC-CMs. Three mechanisms have been proposed to underlie leaky RyR2 channels: dissociation of a channel-stabilizing protein (calstabin2) from RyR2 [34] , defective inter-domain folding of RyR2 [35] , and changes in the sensitivity of RyR2 to cytosolic and luminal Ca 2+ [36] . The augmented binding of calstabin2 to RyR2 is the only mechanism demonstrated to underlie the effect of S107. Regarding the binding site of calstabin2 on RyR2, the central domain of RyR2 has been reported to interact with calstabin2 [37] . However, Zissimopoulos and colleagues demonstrated that the C-terminal domain (containing the transmembrane domain) of RyR2 interacts with calstabin2 [38] . In our CPVT model, S107 might exert an antiarrhythmic effect by improving binding between calstabin2 and the transmembrane domain of RyR2. S107 can also prevent stress-induced cognitive dysfunction [39] , the progression of heart failure [40] , and muscle weakness in aging [41] or Duchenne muscular dystrophy [42] . The lead Rycal program is in phase 2 clinical studies for the treatment of heart failure and arrhythmias. These compounds may have great promise for treating patients with CPVT. There are several limitations in this study. We analyzed CPVT-hiPSC-CMs derived from one RyR2 mutation. It is therefore unclear whether the findings in our model would be confirmed in another CPVT hiPSC-model harboring different mutations in RyR2 or other candidate genes. Other limitations are immature electrophysiological and structural properties of hiPSC-CMs compared to adult CMs, and a fundamental issue that we have developed a cellbased model which did not recapitulate the complex environment of a mammalian heart.
Conclusions
We generated a stem cell-based CPVT model harboring an RyR2 mutation in the transmembrane domain, and it successfully recapitulated the disease phenotype. Electrical pacing was highly useful for analyzing arrhythmogenic features in CPVT-hiPSC-CMs, and the antiarrhythmic effect of S107 was confirmed in this model. This CPVT hiPSC-based model assessed with electrical pacing is a powerful tool that will provide us with a better understanding of the underlying mechanisms and new approaches for screening drugs to establish personalized medicine. 
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